Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 405 of the 405 references it cites were found in a registry or an index; 201 of the 354 sources its claims cite were checked for support.

Mechanisms, efficacy, and future perspectives of cellular-based therapies for liver fibrosis/cirrhosis: focusing on mesenchymal stromal cells

Open access
Pan, Xuan, Gao, Tianyun, Wang, Bin · 2025 · Cell & Bioscience

Abstract

Liver fibrosis/cirrhosis, characterized by excessive deposition of extracellular matrix (ECM) and formation of fibrous scars, arises from chronic liver injury and poses a significant global health burden. Although liver transplantation remains the sole curative option, its application is limited by donor scarcity, immune rejection risks, and high costs. Cellular therapies, particularly those based on mesenchymal stromal cells (MSCs), have emerged as a promising alternative. This review comprehensively examines the therapeutic mechanisms and clinical efficacy of diverse cell therapies for liver cirrhosis, with a focus on MSC-based approaches. MSCs demonstrate multifaceted advantages, including immunomodulatory properties, anti-fibrotic effects (via hepatic stellate cell inhibition and ECM remodeling), promotion of hepatocyte regeneration, and mitigation of oxidative stress. Their low immunogenicity facilitates allogeneic transplantation, while their availability from multiple sources (e.g., bone marrow, umbilical cord, adipose tissue) supports scalable clinical application. We analyze 95 registered clinical trials (73 MSC-focused), highlighting consistent safety profiles but variable efficacy, influenced by factors such as cell source, preparation protocols, administration route, and patient heterogeneity. Key challenges include standardizing MSC production (donor selection, culture conditions, cryopreservation), optimizing delivery methods (intravenous vs. intrahepatic routes), and defining dosing regimens. Strategies to enhance MSC efficacy-such as genetic modification, biomaterial engineering, combinatorial therapies (e.g., with endothelial progenitor cells or macrophages), and MSC-derived extracellular vesicles-are critically evaluated. Future perspectives emphasize the need for large-scale randomized trials, single-cell technologies to resolve MSC heterogeneity, and organoid models to refine therapeutic protocols.

Overview

CoChat Summary

## TL;DR

This review argues that mesenchymal stromal cell (MSC) therapy is the most promising cell-based approach for liver fibrosis/cirrhosis because it acts through multiple mechanisms, including immunomodulation, anti-fibrotic signaling, regeneration, and oxidative-stress control. It also finds that clinical evidence is encouraging overall, but efficacy varies and the field still needs standardized production, delivery, and dosing protocols.

## Key findings

  • The authors systematically searched ClinicalTrials.gov through August 27, 2025 and identified 95 clinical trials of cell therapy for liver cirrhosis/fibrosis; 73 of these focused on MSCs.
  • Across the clinical trials reviewed, none reported severe adverse events related to MSC therapy; the most common side effect was fever, which was manageable with antipyretics.
  • In the largest cited randomized controlled Phase II study, 219 patients with HBV-related decompensated liver cirrhosis received 0.5 × 10^6 allogeneic UC-MSCs/kg intravenously on three occasions at 4-week intervals and had a significantly higher overall survival rate from 13 to 75 months, with improved ALB, PTA, CHE, and TBIL over 48 weeks.
  • Another China trial with 201 patients with decompensated liver cirrhosis reported a significantly higher overall survival rate after MSC therapy during a 5-year follow-up.
  • The review highlights that MSCs can attenuate fibrosis by blocking hepatic stellate cells, promoting ECM degradation/remodeling, enhancing hepatocyte proliferation, and reducing oxidative stress.

## Methods

  • Narrative review plus systematic clinical-trial search: the authors searched ClinicalTrials.gov from inception to August 27, 2025 for trials of “cell” treatment for “liver cirrhosis OR liver fibrosis.”
  • They extracted trial characteristics including NCT number, phase, status, country, cell source, administration route, and main results, then categorized and visualized the findings.
  • They also synthesized preclinical and clinical literature on mechanisms and efficacy, with special attention to MSCs.

## Limitations

  • The paper states that there is no consensus on several core clinical parameters, including cell source, preparation, delivery route, and dose, which makes trial results heterogeneous.
  • It states that many findings are still based on animal studies or early-phase trials, and that further research is needed to confirm mechanisms and optimize clinical use.
  • Evident from the text: the clinical evidence base is limited by variable study design, incomplete posted results, and differing follow-up durations, and the review itself is not a new interventional study (this is evident from the text).

Model-written summary of a shortened version of the paper’s full text (it is longer than we read). Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1186/s13578-025-01520-9

Cites

405 of 405 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 In healthy livers, immune cells are scattered through the hepatic sinusoids, particularly resident KCs acting as intravascular sentinels. Following injury, KCs respond rapidly, triggering a pro-inflammatory response. Various immune cells (e.g., neutrophils, monocytes, and lymphocytes) are recruited to the site of injury via chemokine secretion. Together with liver resident cells (e.g., KCs, HSCs, and LSECs), they release pro-inflammatory signals (cytokines, lipid mediators, and ROS), leading to hepatocyte necrosis or apoptosis. In turn, necrotic or apoptotic hepatocytes emit massive amounts of DAMPs, amplifying inflammation and promoting cell death. DAMPs, along with pro-inflammatory mediators (e.g., TGF-β and ROS) from activated immune cells, can initiate fibrogenesis by activating HSCs. Activated HSCs secrete components of ECM into the space of Disse (a thin perisinusoidal area between LSECs and hepatocytes), replacing normal liver parenchyma and forming the fibrous scar. During this process, LSECs lose fenestrae and undergo capillarization, which does not prevent the activation of HSCs, accompanied by the loss of microvilli on the hepatocytes, compromising the exchange of nutrients, metabolites, and signaling molecules. In advanced fibrosis, fibrogenesis predominates over fibrolysis, and non-fibrogenic type IV collagen is replaced by fibrillar type I and III collagen. Abbreviations: KC: Kupffer cell; HSC: hepatic stellate cell; LSEC: liver sinusoidal endothelial cells; ROS: reactive oxygen species; DAMP: damage-associated molecular pattern; TGF-β: transforming growth factor-β; ECM: extracellular matrix. Created with BioRender.com.
Fig. 1 In healthy livers, immune cells are scattered through the hepatic sinusoids, particularly resident KCs acting as intravascular sentinels. Following injury, KCs respond rapidly, triggering a pro-inflammatory response. Various immune cells (e.g., neutrophils, monocytes, and lymphocytes) are recruited to the site of injury via chemokine secretion. Together with liver resident cells (e.g., KCs, HSCs, and LSECs), they release pro-inflammatory signals (cytokines, lipid mediators, and ROS), leading to hepatocyte necrosis or apoptosis. In turn, necrotic or apoptotic hepatocytes emit massive amounts of DAMPs, amplifying inflammation and promoting cell death. DAMPs, along with pro-inflammatory mediators (e.g., TGF-β and ROS) from activated immune cells, can initiate fibrogenesis by activating HSCs. Activated HSCs secrete components of ECM into the space of Disse (a thin perisinusoidal area between LSECs and hepatocytes), replacing normal liver parenchyma and forming the fibrous scar. During this process, LSECs lose fenestrae and undergo capillarization, which does not prevent the activation of HSCs, accompanied by the loss of microvilli on the hepatocytes, compromising the exchange of nutrients, metabolites, and signaling molecules. In advanced fibrosis, fibrogenesis predominates over fibrolysis, and non-fibrogenic type IV collagen is replaced by fibrillar type I and III collagen. Abbreviations: KC: Kupffer cell; HSC: hepatic stellate cell; LSEC: liver sinusoidal endothelial cells; ROS: reactive oxygen species; DAMP: damage-associated molecular pattern; TGF-β: transforming growth factor-β; ECM: extracellular matrix. Created with BioRender.com.CC BY-NC-ND · PubMed Central
Fig. 2 Chronologically, the utilization of various cell types in clinical trials for liver cirrhosis treatment began with hepatocytes in 1992 followed by MNCs, HSPCs, MSCs, LPCs, EPCs, and macrophages. These cell therapies possess distinct therapeutic mechanisms (green box), advantages (purple box), and disadvantages (yellow box). Abbreviations: MNC: mononuclear cell; HSPC: hematopoietic stem/progenitor cell; MSC: mesenchymal stromal cell; LPC: liver/hepatic progenitor cell; EPC: endothelial progenitor cell. Created with BioRender.com.
Fig. 2 Chronologically, the utilization of various cell types in clinical trials for liver cirrhosis treatment began with hepatocytes in 1992 followed by MNCs, HSPCs, MSCs, LPCs, EPCs, and macrophages. These cell therapies possess distinct therapeutic mechanisms (green box), advantages (purple box), and disadvantages (yellow box). Abbreviations: MNC: mononuclear cell; HSPC: hematopoietic stem/progenitor cell; MSC: mesenchymal stromal cell; LPC: liver/hepatic progenitor cell; EPC: endothelial progenitor cell. Created with BioRender.com.CC BY-NC-ND · PubMed Central
Fig. 3 Clinical trials of cell therapy for liver cirrhosis. A An overall of clinical trials of cell therapy for liver cirrhosis classified by cell type. B Clinical trials of MSC and MSC combined therapy for liver cirrhosis. C Clinical trials of MSC combined therapy for liver cirrhosis. D Clinical trials of MSC therapy for liver cirrhosis classified by country. E Clinical trials of MSC therapy for liver cirrhosis classified by phase. F Clinical trials of MSC therapy for liver cirrhosis classified by status. G Clinical trials of liver fibrosis based on autologous and allogeneic transplantation of MSCs. H Clinical trials of liver fibrosis based on different sources of MSCs. I Clinical trials of liver fibrosis based on delivery routes of MSCs. J Clinical trials of MSC-EV-related therapy for liver cirrhosis. The data showed the number of corresponding clinical trials registered on https://clinicaltrials.gov/ [270]. Abbreviations: MSC: mesenchymal stromal cell. Created with GraphPad Prism 10.2.3 (GraphPad Software, CA, USA)
Fig. 3 Clinical trials of cell therapy for liver cirrhosis. A An overall of clinical trials of cell therapy for liver cirrhosis classified by cell type. B Clinical trials of MSC and MSC combined therapy for liver cirrhosis. C Clinical trials of MSC combined therapy for liver cirrhosis. D Clinical trials of MSC therapy for liver cirrhosis classified by country. E Clinical trials of MSC therapy for liver cirrhosis classified by phase. F Clinical trials of MSC therapy for liver cirrhosis classified by status. G Clinical trials of liver fibrosis based on autologous and allogeneic transplantation of MSCs. H Clinical trials of liver fibrosis based on different sources of MSCs. I Clinical trials of liver fibrosis based on delivery routes of MSCs. J Clinical trials of MSC-EV-related therapy for liver cirrhosis. The data showed the number of corresponding clinical trials registered on https://clinicaltrials.gov/ [270]. Abbreviations: MSC: mesenchymal stromal cell. Created with GraphPad Prism 10.2.3 (GraphPad Software, CA, USA)CC BY-NC-ND · PubMed Central
Fig. 4 Parameters affecting the heterogeneity and therapeutic efficacy of MSCs. A Cell manufacturing. B Administration routes and derivative types. C Conditions of patients. Abbreviations: MSC: mesenchymal stromal cell. Created with BioRender.com
Fig. 4 Parameters affecting the heterogeneity and therapeutic efficacy of MSCs. A Cell manufacturing. B Administration routes and derivative types. C Conditions of patients. Abbreviations: MSC: mesenchymal stromal cell. Created with BioRender.comCC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

158 Valid · 5 Not valid · 91 Not checked · 52 Own results and interpretations

163 more claims · 82 with their cited sources checked

Create a free account to see all 306 claims and to verify the 42 references still open.

See all claims — free account
  • Probably not a substantial claim. 19
  • It may state two separate claims as one. 128
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Citations

Cites

Show all 405 references

Research works printed but not linked: 4

  1. Mohamadnejad M, Alimoghaddam K, Mohyeddin-Bonab M, Bagheri M, Bashtar M, Ghanaati H, et al. Phase 1 trial of autologous bone marrow mesenchymal stem cell transplantation in patients with decompensated liver cirrhosis. Arch Iran Med. 2007;10:459–66.
  2. Nikeghbalian S, Pournasr B, Aghdami N, Rasekhi A, Geramizadeh B, Hosseini Asl SMK, et al. Autologous transplantation of bone marrow-derived mononuclear and CD133(+) cells in patients with decompensated cirrhosis. Arch Iran Med. 2011;14:12–7.
  3. Picardi M, De Rosa G, Selleri C, Scarpato N, Soscia E, Martinelli V, et al. Spleen enlargement following recombinant human granulocyte colony-stimulating factor administration for peripheral blood stem cell mobilization. Haematologica. 2003;88:794–800.
  4. Vosough M, Moossavi S, Mardpour S, Akhlaghpoor S, Azimian V, Jarughi N, et al. Repeated intraportal injection of mesenchymal stem cells in combination with pioglitazone in patients with compensated cirrhosis: a clinical report of two cases. Arch Iran Med. 2016;19:131–6.

Cited by

See all 2

Metadata

Authors
Pan, X., Gao, T., & Wang, B.
Affiliations
  • Nanjing Normal University (CN)
  • Nanjing Drum Tower Hospital (CN)
Corresponding author
Wang, Bin
Venue
Cell & Bioscience
Published
2025-12-30
Volume
16
Issue
1
Pages
11-11
ISSN
2045-3701 (ISSN-L)
OpenAlex
W7117538003
Cited by
2
References
405
Citations by year
2026: 2
FWCI
0.31
Type
journal article
Language
en
Open access
Licence
Locations
  • Cell & Bioscience (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
National Natural Science Foundation of China (82070459, 82270701)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
  • Health Sciences › Medicine › Hepatology › Liver physiology and pathology
  • Health Sciences › Medicine › Hepatology › Liver Disease and Transplantation
Keywords
liver fibrosis, liver cirrhosis, mesenchymal stem cells, cell therapy, extracellular matrix remodeling, hepatic stellate cells, hepatocyte regeneration, oxidative stress, immunomodulation, cell delivery routes, biomaterials engineering, endothelial progenitor cells, macrophages, organoids, single-cell analysis, MSC heterogeneity

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Mechanisms, efficacy, and future perspectives of cellular-based therapies for liver fibrosis/cirrhosis: focusing on mesenchymal stromal cells. https://app.cochat.ai/papers/10.1186/s13578-025-01520-9
The paper
Pan, X., Gao, T., & Wang, B. (2025). Mechanisms, efficacy, and future perspectives of cellular-based therapies for liver fibrosis/cirrhosis: focusing on mesenchymal stromal cells. Cell & Bioscience. https://doi.org/10.1186/s13578-025-01520-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.